Evidence map›Paper›PMID 36350608›Full record

ArticleNucleic acids research2023

Annotation and evaluation of base editing outcomes in multiple cell types using CRISPRbase.

Jibiao Fan, Leisheng Shi, Qi Liu, Zhipeng Zhu, Fan Wang, Runxian Song, Jimeng Su, Degui Zhou, Xiao Chen, Kailong Li and 3 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jibiao FanInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Leisheng ShiInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Qi LiuRice Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.
Zhipeng ZhuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Fan WangCollege of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu Province 225009, China.
Runxian SongRice Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.
Jimeng SuCollege of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu Province 225009, China.
Degui ZhouRice Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China.
Xiao ChenLaboratory of Marine Protozoan Biodiversity & Evolution, Marine College, Shandong University, Weihai 264209, China.
Kailong LiDepartment of Biochemistry and Biophysics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Lixiang XueInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.
Lichao SunState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fengbiao MaoInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0003-0852-4266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-Cas base editing (BE) system is a powerful tool to expand the scope and efficiency of genome editing with single-nucleotide resolution. The editing efficiency, product purity, and off-target effect differ among various BE systems. Herein, we developed CRISPRbase (http://crisprbase.maolab.org), by integrating 1 252 935 records of base editing outcomes in more than 50 cell types from 17 species. CRISPRbase helps to evaluate the putative editing precision of different BE systems by integrating multiple annotations, functional predictions and a blasting system for single-guide RNA sequences. We systematically assessed the editing window, editing efficiency and product purity of various BE systems. Intensive efforts were focused on increasing the editing efficiency and product purity of base editors since the byproduct could be detrimental in certain applications. Remarkably, more than half of cancer-related off-target mutations were non-synonymous and extremely damaging to protein functions in most common tumor types. Luckily, most of these cancer-related mutations were passenger mutations (4840/5703, 84.87%) rather than cancer driver mutations (863/5703, 15.13%), indicating a weak effect of off-target mutations on carcinogenesis. In summary, CRISPRbase is a powerful and convenient tool to study the outcomes of different base editors and help researchers choose appropriate BE designs for functional studies.

Indexed as

Gene EditingNeoplasmsCRISPR-Cas SystemsHumansMutation

Identifiers

PMID36350608
PMCPMC9825451

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.